跳至主要内容
临床试验/NCT01266434
NCT01266434已完成3 期

The Additive Anti-inflammatory Effect of Simvastatin in Combination With Inhaled Corticosteroids on p38 MAPK in Asthma

Mahidol University1 个研究点 分布在 1 个国家目标入组 44 人开始时间: 2011年1月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
入组人数
44
试验地点
1
主要终点
Sputum eosinophils

研究概览

简要总结

To test whether simvastatin has an additional anti-inflammatory effects on p38 MAPK, a signaling molecule for inflammation in inhaled steroid-treated asthmatics.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • mild-to-moderate persistent asthmatics
  • FEV1 = OR > 50% of predicted

排除标准

  • Previous history of renal disease or serum creatinine is more than 2 mg/dl.
  • Previous history of liver disease.
  • Pregnancy or lactation.
  • Are already receiving or are known to be allergic to statins or to have developed myositis.
  • Have an asthma exacerbation requiring treatment with oral corticosteroids during the 3 months prior to the commencement of study entry.
  • Being treated with immunosuppressive agents.
  • Unwilling to cooperate the study.

研究组 & 干预措施

simvastatin

Experimental

干预措施: Simvastatin (Drug)

B1-6-12

Placebo Comparator

干预措施: Simvastatin (Drug)

B1-6-12

Placebo Comparator

干预措施: B1-6-12 (Drug)

结局指标

主要结局

Sputum eosinophils

时间窗: 8 weeks

To determine the additive effect of simvastatin on airway inflammation in ICS-treated patients with persistent asthma by measuring eosinophil counts in induced sputum and on lung function (FEV1)

次要结局

  • Phosphorylated p38 MAPK in sputum cells(8 weeks)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Kittipong Maneechotesuwan

Professor

Mahidol University

研究点 (1)

Loading locations...

相似试验